Thymidine phosphorylase

Drug Combination Meets Survival Endpoint in Phase III Pivotal Trial Involving Participants With Refractory Metastatic Colorectal Cancer

Retrieved on: 
Monday, September 12, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Neuroscience, Lists of diseases, Safety, Awareness, Cell proliferation, CRC, Social media, Patient, Oncology, Cardiology, Foundation, Human, Taiho Pharmaceutical, Urology, Quality of life, Disease, Organic, Oxaliplatin, Allergy, Teaching hospital, International Agency for Research on Cancer, Growth, Metabolism, Thymidine phosphorylase, Colorectal cancer, International development, DCR, TP, DNA, Trifluridine/tipiracil, Trifluridine, Partnership, Irinotecan, Progression-free survival, Research and development, Group, Health, Incidence, Twitter, World Health Organization, LinkedIn, Survival, ORR, Caregiver, Death, Heart, Multimedia, PFS, Pharmaceutical industry, Medical imaging, Birth control, OS, Research, Bevacizumab, Laboratoires Servier, Facebook, Cancer

Combining trifluridine/tipiracil with bevacizumab demonstrated the potential to extend survival in these patients who have limited therapeutic options.

Key Points: 
  • Combining trifluridine/tipiracil with bevacizumab demonstrated the potential to extend survival in these patients who have limited therapeutic options.
  • New treatment options are urgently needed as we seek to reduce the growing global burden of colorectal cancer.
  • SUNLIGHT is a multinational, open-label, active-controlled, two-arm Phase III trial to investigate the efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil alone, in patients with refractory mCRC following two chemotherapy regimens.
  • The primary objective was to demonstrate the superiority of trifluridine/tipiracil plus bevacizumab over trifluridine/tipiracil alone, in terms of OS (primary endpoint).

Servier announces outcome from the primary analysis of the Phase III SOLSTICE trial assessing LONSURF® (trifluridine/tipiracil) + bevacizumab in a 1st line setting for patients with unresectable mCRC non-eligible for intensive therapy

Retrieved on: 
Friday, October 22, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, VEGF, Phase, EGFR, Social, Quality of life, Cardiology, Cell proliferation, Group, Cancer, Trifluridine, Thymidine phosphorylase, Social media, Adenocarcinoma, Colorectal cancer, TP, Human, Lead, Patient, Capecitabine, Foundation, Gastrointestinal cancer, Survival rate, Taiho Pharmaceutical, Trifluridine/tipiracil, Adult, MGC, Congress, CRC, Research and development, Neuroscience, Oxaliplatin, Growth, Lists of diseases, Metabolism, Vascular endothelial growth factor A, Bevacizumab, Heart, Irinotecan, DNA, Pharmaceutical industry, Medical imaging

SOLSTICE was designed to evaluate the superiority of LONSURF (trifluridine/tipiracil) + bevacizumab over capecitabine + bevacizumab in 1st line unresectable metastatic colorectal cancer (mCRC) in patients non-eligible for intensive therapy.

Key Points: 
  • SOLSTICE was designed to evaluate the superiority of LONSURF (trifluridine/tipiracil) + bevacizumab over capecitabine + bevacizumab in 1st line unresectable metastatic colorectal cancer (mCRC) in patients non-eligible for intensive therapy.
  • D., Head of Late Stage and Life Cycle Management, and Deputy Head Oncology and Immuno-Oncology Therapeutic Area, Servier.
  • The clinical value of LONSURF in its current indications remains unchanged, and the ongoing Phase III SUNLIGHT trial (LONSURF + bevacizumab versus LONSURF in 3rd line mCRC) is proceeding as planned.
  • SOLSTICE is an open-label, randomized, multicentre Phase III trial in 856 unresectable metastatic colorectal cancer patients who are not candidates for, or do not require, intensive therapy.

Entrada Therapeutics Announces ENTR-501 for the Treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)

Retrieved on: 
Wednesday, January 8, 2020
Enzymes, Articles, Life sciences, Thymidine phosphorylase, Rare diseases, Mitochondrial neurogastrointestinal encephalopathy syndrome, Inborn errors of carbohydrate metabolism, Biopharmaceutical, Glycogen storage disease type V, Mitochondrion, ECGF1

BOSTON, Jan. 8, 2020 /PRNewswire/ --Entrada Therapeutics, Inc. a biotechnology company dedicated to transforming the treatment of devastating diseases through the intracellular delivery of biologics, today announced that it is developing ENTR-501, a novel thymidine phosphorylase enzyme replacement therapy, for the treatment of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE).

Key Points: 
  • BOSTON, Jan. 8, 2020 /PRNewswire/ --Entrada Therapeutics, Inc. a biotechnology company dedicated to transforming the treatment of devastating diseases through the intracellular delivery of biologics, today announced that it is developing ENTR-501, a novel thymidine phosphorylase enzyme replacement therapy, for the treatment of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE).
  • "There is a critical need for a therapeutic option that addresses the underlying thymidine phosphorylase deficiency in MNGIE patients."
  • Entrada's EEV technology enables the functional intracellular delivery of biologics like thymidine phosphorylase by facilitating improved cellular uptake and efficient endosomal escape.
  • Entrada Therapeutics' mission is to treat devastating diseases through the intracellular delivery of biologics.